Get the Stockscreener App
8.12
0.62%
0.010
Adicet Bio Inc stock is traded at $8.12, with a volume of 53,571.
It is up +0.62% in the last 24 hours and down -7.59% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
See More
Previous Close:
$8.11
Open:
$8.15
24h Volume:
53,571
Relative Volume:
0.57
Market Cap:
$76.19M
Revenue:
$24.99M
Net Income/Loss:
$-108.83M
P/E Ratio:
-0.5403
EPS:
-15.0286
Net Cash Flow:
$-91.62M
1W Performance:
-11.40%
1M Performance:
-7.59%
6M Performance:
+19.82%
1Y Performance:
-14.49%
1-Day Range:
$7.925
$8.285
1-Week Range:
$7.42
$9.50
52-Week Range:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
8.15 | 75.35M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
530.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.00 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.27 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.69 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.87 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio, Inc. Revenue Breakdown – NASDAQ:ACET - TradingView
Adicet Bio Inc (ACET) Balance Sheet - TradingKey
Adicet Bio Inc (ACET) Cash Flow - TradingKey
Adicet Bio: A 400% Upside Bet on Gamma Delta T-Cell Data - Kavout | AI
Adicet Bio Inc Revenue Breakdown – TRADEGATE:1IJ - TradingView
Adicet Bio Inc (ACET) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Adicet Bio Inc (ACET) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adicet Bio Inc (ACET) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adicet Bio Inc (ACET) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACET|Adicet Bio Inc|Price:8.140|Chg%:+0.350 - TradingKey
Adicet Bio Market Sentiment - Benzinga España
Adicet Bio Inc (ACET) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference - BioSpace
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Price to earnings forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
Enterprise value to revenue forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
ACET Q1 2026 Earnings: Narrower Loss Beats Expectations Amid Pre-Revenue StageRevenue Surprise History - dars.gov.et
Adicet Bio (ACET) Proxy filing Summary - Quartr
Are medical stocks lagging Adicet Bio (ACET) this year? - MSN
Adicet Bio (ACET) Stock Analysis Report | Financials & Insights - Benzinga España
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adicet Bio, Inc.(NasdaqCM: ACET) added to Russell Microcap Value Benchmark Index - marketscreener.com
Adicet Bio, Inc.(NasdaqCM: ACET) added to Russell Microcap Index - marketscreener.com
Adicet Bio, Inc.(NasdaqCM: ACET) added to Russell 3000E Index - marketscreener.com
ACET Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Shares HigherBook Value Growth - dars.gov.et
1IJ Forecast — Price Target — Prediction for 2027 - TradingView
Adicet Bio Inc Actuals & Estimates (MUN:1IJ) - TradingView
ACET Forecast — Price Target — Prediction for 2027 - TradingView
Adicet Bio Inc Actuals & Estimates (TRADEGATE:1IJ) - TradingView
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Form 4 Adicet Bio Inc For: 23 June By Investing.com - Investing.com Nigeria
Adicet Bio (ACET) CEO Chen Schor receives 55,000 stock options at $8.10 - Stock Titan
Adicet Bio (ACET) grants CSO Blake Aftab 55,000 stock options - Stock Titan
Director at Adicet Bio (NASDAQ: ACET) receives 4,200 stock options grant - Stock Titan
Director at Adicet Bio (ACET) awarded 4,200 options at $8.10 strike - Stock Titan
Adicet Bio (ACET) director receives stock options for 4,200 shares at $8.10 - Stock Titan
Adicet Bio (ACET) director receives 4,200 stock options at $8.10 strike - Stock Titan
Director Katie Peng receives 4,200 Adicet Bio (ACET) stock options at $8.10 - Stock Titan
Director at Adicet Bio (ACET) receives 4,200 stock options award - Stock Titan
ACET Q1 2026 Earnings: EPS Beats Estimates by 40.7% as Clinical Progress ContinuesEBITDA Analysis - dars.gov.et
Adicet Bio Stockholders Back Directors, Pay and Auditor - TipRanks
Adicet Bio (ACET) investors back board nominees, pay and KPMG at 2026 meeting - Stock Titan
Adicet Bio Inc (ACET) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adicet Bio Inc (ACET) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adicet Bio Inc (ACET) Institutional Confidence - TradingKey
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adicet Bio Inc Stock (ACET) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 19 '26 |
Buy |
7.21 |
74,268 |
535,472 |
1,107,873 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 18 '26 |
Buy |
7.04 |
74,577 |
525,022 |
1,033,605 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 08 '26 |
Sale |
6.42 |
72,939 |
468,082 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 07 '26 |
Sale |
6.52 |
31,719 |
206,765 |
32,523 |
0.79%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):